Samsung Bioepis cancer drug under review by FDA

Home > Business > Industry

print dictionary print

Samsung Bioepis cancer drug under review by FDA

Samsung Bioepis said Wednesday that the U.S. Food and Drug Administration has begun reviewing its license application for a cancer-fighting biosimilar called SB3.

A biosimilar is a drug with active properties similar to a previously licensed one. SB3 references Herceptin, a breast cancer drug from Swiss pharmaceutical company Roche.

According to Samsung Bioepis, SB3 is the company’s first oncological biosimilar submitted for regulatory review in the United States.

By Kim Jee-hee

More in Industry

EuCorVac-19 vaccine gets greenlight for trials

Tesla model to lose government subsidies

Jailed Lee vows to support Samsung compliance committee

Samsung Display will make display with higher refresh rate

Clean start to the Lunar New Year

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now